| human | Q5 |
| P496 | ORCID iD | 0000-0002-4986-5326 |
| P1153 | Scopus author ID | 7003277368 |
| P734 | family name | Klion | Q86552717 |
| Klion | Q86552717 | ||
| Klion | Q86552717 | ||
| P735 | given name | Amy | Q481809 |
| Amy | Q481809 | ||
| D. | Q19803500 | ||
| D. | Q19803500 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q44077964 | A high malaria reinfection rate in children and young adults living under a low entomological inoculation rate in a periurban area of Bamako, Mali |
| Q47873366 | A novel developmentally regulated galectin of Onchocerca volvulus |
| Q34612544 | A randomized trial of doxycycline for Mansonella perstans infection |
| Q59291607 | AETIOLOGY OF OESOPHAGEAL CANCER |
| Q28543545 | Analysis of nematode motion using an improved light-scatter based system |
| Q35913553 | Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome |
| Q36942170 | Approach to the therapy of hypereosinophilic syndromes |
| Q34534119 | Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report |
| Q36125719 | At homeostasis filarial infections have expanded adaptive T regulatory but not classical Th2 cells |
| Q35565533 | Biologic therapies targeting eosinophils: current status and future prospects |
| Q35167144 | CD2 identifies a monocyte subpopulation with immunoglobulin E-dependent, high-level expression of Fc epsilon RI |
| Q59800407 | Charcot-Leyden crystals: solving an enigma |
| Q43218742 | Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome |
| Q33881297 | Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes |
| Q54352895 | Defective gamma-interferon production in peripheral blood leukocytes of patients with acute tuberculosis. |
| Q34225936 | Development of a suspension array assay in multiplex for the simultaneous measurement of serum levels of four eosinophil granule proteins |
| Q88608121 | Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes |
| Q59291462 | Diethylcarbamazine (DEC) |
| Q34551802 | Dysregulation of interleukin 5 expression in familial eosinophilia |
| Q34160164 | Elevated levels of plasma angiogenic factors are associated with human lymphatic filarial infections |
| Q59291525 | Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome |
| Q33962299 | Eosinophilia: introduction |
| Q36847447 | Eosinophils in vasculitis: characteristics and roles in pathogenesis |
| Q35146265 | Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder |
| Q36112316 | Expanded numbers of circulating myeloid dendritic cells in patent human filarial infection reflect lower CCR1 expression |
| Q35946132 | Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus. |
| Q34975799 | Filaria-induced monocyte dysfunction and its reversal following treatment |
| Q36125714 | Filarial infection suppresses malaria-specific multifunctional Th1 and Th17 responses in malaria and filarial coinfections |
| Q45885639 | Filarial infections in travelers and immigrants |
| Q34470013 | Filariasis attenuates anemia and proinflammatory responses associated with clinical malaria: a matched prospective study in children and young adults |
| Q33312446 | Filariasis in travelers presenting to the GeoSentinel Surveillance Network |
| Q24804532 | Genetic heterogeneity in Loa loa parasites from southern Cameroon: A preliminary study |
| Q59291435 | Glucocorticoid-induced eosinopenia in humans can be linked to early transcriptional events |
| Q36734178 | Highly heterogeneous, activated, and short-lived regulatory T cells during chronic filarial infection |
| Q59291504 | How I treat hypereosinophilic syndromes |
| Q36000858 | How I treat hypereosinophilic syndromes. |
| Q33692709 | Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy |
| Q37561133 | Hypereosinophilic syndrome: current approach to diagnosis and treatment. |
| Q36834826 | ICON: Eosinophil Disorders |
| Q35490676 | IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis |
| Q45204134 | Imatinib-responsive hypereosinophilia in a patient with B cell ALL. |
| Q36199161 | Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN-γ in filaria-malaria co-infection |
| Q48691451 | KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities |
| Q37276382 | KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells |
| Q36573038 | Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes |
| Q37350308 | Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection |
| Q37605322 | Marked and persistent eosinophilia in the absence of clinical manifestations. |
| Q34176798 | Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome |
| Q59291475 | Miscellaneous Filariae |
| Q36813544 | Molecular identification of Wolbachia from the filarial nematode Mansonella perstans |
| Q27824799 | Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome |
| Q53641005 | Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. |
| Q34444620 | Novel targeted therapies for eosinophil-associated diseases and allergy |
| Q36763565 | Novel targeted therapies for eosinophilic disorders |
| Q52585022 | Onchocerciasis in a nonendemic population: clinical and immunologic assessment before treatment and at the time of presumed cure. |
| Q37462905 | Patent filarial infection modulates malaria-specific type 1 cytokine responses in an IL-10-dependent manner in a filaria/malaria-coinfected population |
| Q27003331 | Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field |
| Q36129414 | Peripheral blood stem cell transplant-related Plasmodium falciparum infection in a patient with sickle cell disease |
| Q53600138 | Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis. |
| Q52590515 | Pruritus and eosinophilia in a 14-year-old girl from Liberia. |
| Q33624359 | Rapid development of migratory, linear, and serpiginous lesions in association with immunosuppression |
| Q59291567 | Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti–IL-5 antibody SCH55700 |
| Q40116200 | Recent advances in understanding eosinophil biology |
| Q36103687 | Refining the definition of hypereosinophilic syndrome |
| Q36141619 | Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing |
| Q42870469 | Reply: To PMID 23987798. |
| Q47801019 | Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome |
| Q36162246 | Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome |
| Q31123406 | Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll-SXP-1, are highly specific for Loa loa infection |
| Q91253254 | Siglec-7 on peripheral blood eosinophils: Surface expression and function |
| Q33829714 | Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance |
| Q48294546 | The FAR proteins of filarial nematodes: secretion, glycosylation and lipid binding characteristics |
| Q37561562 | The consequences of not having eosinophils. |
| Q28307714 | The eosinophil surface receptor epidermal growth factor-like module containing mucin-like hormone receptor 1 (EMR1): a novel therapeutic target for eosinophilic disorders |
| Q44565219 | The etiology of severe anemia in a village and a periurban area in Mali |
| Q59291592 | The relationship between serum IgE and surface levels of FcϵR on human leukocytes in various diseases: Correlation of expression with FcϵRI on basophils but not on monocytes or eosinophils |
| Q35624885 | The role of eosinophils in host defense against helminth parasites |
| Q35857340 | Therapeutic approaches to patients with hypereosinophilic syndromes |
| Q34762186 | Treatment of patients with the hypereosinophilic syndrome with mepolizumab |
| Q35019772 | Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels |
| Q36206063 | Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). |
| Q37153039 | Wuchereria bancrofti transmission pattern in southern Mali prior to and following the institution of mass drug administration |
Search more.